Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 5/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125703 | 0.87 | HTR6 (0.57) | OPRM1BRPF1BRD4MAP2K4HTR6 | |
| SCHEMBL13355716 | 0.85 | BRD4 (0.41) | OPRM1BRPF1BRD4MAP2K4HTR6 | |
| SCHEMBL2150876 | 0.82 | EPHX1 (0.46) | HTR6SMN1; SMN2EPHX1EPHX2 | |
| SCHEMBL13355600 | 0.81 | HTR6 (0.54) | OPRM1BRPF1BRD4MAP2K4HTR6 | |
| SCHEMBL15946037 | 0.81 | MEN1 (0.46) | OPRM1HTR6MLNRSMN1; SMN2GHSR | |
| SCHEMBL13469209 | 0.79 | OPRM1 (0.54) | OPRM1BRPF1SMN1; SMN2 | |
| SCHEMBL2151236 | 0.79 | CA1 (0.45) | EPHX1 | |
| SCHEMBL10235940 | 0.77 | XIAP (0.40) | — | |
| SCHEMBL14582136 | 0.76 | SMN1; SMN2 (0.59) | OPRM1BRPF1BRD4MAP2K4SMN1; SMN2 | |
| SCHEMBL13565390 | 0.76 | HPGD (0.49) | HTR6MLNRSMN1; SMN2GHSREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-05-26 | — | — | US | disclosed |
| US-9193669-B2 | Compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145198-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | OPRM1 4519/4885BRPF1 3793/4885BRD4 2332/4885 |
| US-20140228443-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, ALDH1A2 | OPRM1 4519/4885BRPF1 3793/4885BRD4 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.